Dr. Perez-Soler on Treatment Options for NSCLC

Roman Perez-Soler, MD
Published Online: Tuesday, February 14, 2012
Roman Perez-Soler, MD, Chairman, Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine of Yeshiva University, talks about the recent advances in treatment options for non-small cell lung cancer (NSCLC).

Perez-Soler states that targeted agents represent the most dramatic changes in the treatment of NSCLC. New agents are available that target subgroups with molecular alterations in EGFR and ALK. These alterations are driver mutations in tumor cells and as a result render high response rates.

Despite the initial response to a medication most tumors will eventually develop resistance. The next step for research is to understand how these tumors develop these resistance mechanisms.

Online CME Activities
Free CME from PER
Clinical Vignettes in Improving Patient Care through Angiogenesis Inhibitors: A Focus on Gastrointestinal Malignancies
Clinical Vignettes in Metastatic Colorectal Cancer: Precision Medicine for Community Oncologists
Evolving Management Strategies for Triple-Negative Breast Cancer
Community Practice Connections™: Current and Emerging Strategies in the Management of Early Breast Cancer
More Reading